Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The proposed trial is a pragmatic, registry based, prospective, randomized (1:1) controlled,
open-label parallel group clinical trial with blinded endpoint assessment of 1600 patients to
test if intravenous tenecteplase (0.25 mg/kg body weight, max dose 25 mg) is non-inferior to
intravenous alteplase (0.9 mg/kg body weight) in patients with acute ischemic stroke
otherwise eligible for intravenous thrombolysis as per standard care. All patients will have
standard of care medical management on an acute stroke unit. There are no additional trial
specific management recommendations. Patients will be followed for approximately 90-120 days.